



Mithra Renews its Board of Directors to Support its Operational Ambitions

Liege, Belgium, 3 November 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces, on the initiative of its outgoing Chairman Marc Coucke, its intention to renew its board of directors in accordance with its Strategic Operating Plan.

Since its IPO in 2015, Mithra had expressed its ambition to become a leading international player in the women's health sector. Focused on research and development, the Belgian biotech company then expanded its range of activities by perfecting the operationalization of its innovative products. This strategy has resulted in the gradual evolution of the different functions within the company. Five years later, Mithra counts nearly 350 employees and is on the brink of the potential commercialization of its first innovative product: the contraceptive pill Estelle®. In order to support and accelerate this development, the renewal of the directors appeared an essential step to the entire board.

By means of this renewal, Mithra will add new profiles whose expertise and competence in the pharmaceutical and financial sector will contribute to ensure the quality and relevance of the directions taken in the development and commercialization of its products. The new board will also be distinguished by a greater number of independent directors.

In doing so, the Board of directors will submit the appointment of the following directors to an extraordinary general meeting for approval as soon as possible:

- **Ajit Shetty**, former Chairman of Janssen Pharmaceutica, a subsidiary of Johnson & Johnson (independent director)
- **Patricia van Dijck**, Market Access & Public Affairs Director at GSK (independent director)
- **Eric Van Den Eynde**, outgoing CEO of ING Belgium (independent director)
- **Stijn Van Rompay**, CEO of the pharmaceutical company Hyloris (independent director)
- **Koen Hoffman**, CEO of Value Square and previously CEO of KBC Securities (independent director)
- **Gaëtan Servais**, CEO of the investment fund Noshag (non-executive director)
- **Jean-Michel Foidart**, Perpetual Secretary of the Royal Academy of Medicine (Academy of Medicine, Prof. Ordinary Gyneco) (Executive Director)
- **Christian Moretti**, previously CEO of the European leader in chemistry PCAS Biosolution (non-executive director)
- **François Fornieri**, CEO of Mithra (Executive Director)

Jean Stéphane, former CEO of GSK Biologicals, who has held a number of senior positions in several pharmaceutical and biotech companies since his departure, is expected to add his expertise from mid-2021, based on his current primary mission: the development of a Covid-19 vaccine in the German biotech company CureVac.

Ajit Shetty will be the proposed candidate for the renewed Chair of the Board. Mr Shetty has served as Chairman of the Board of Janssen Pharmaceutica until 2012 and has led the global supply chain at Johnson & Johnson, the world's leading healthcare company. Elected Flanders Manager of the Year in 2004, Ajit Shetty is also a director of VOKA and a member of GS1. *"I am very honored to join Mithra, a leading biotech company that, through the development of innovative products, can make a real difference in women's health."*

Until the Extraordinary General Meeting that will be charged with approving this proposal for renewal of the board of directors, Patricia van Dijck will assume the chairmanship ad interim of the Board of Directors following the resignation of its chairman and certain directors.

Marc Coucke, outgoing Chairman of the Board of Directors of Mithra Women's Health: *"I leave Mithra's Board of Directors with a great deal of pride in view of how far we have come in these last five years. The outgoing directors have succeeded in raising Mithra's ambitions high and it is with a sense of accomplishment that they will hand over their places to new colleagues to best accompany Mithra in a new stage of its ambitious journey. This step concludes the strategic phase developed with the members of the Executive Committee in 2016. I will continue to closely support the evolution of the group as a shareholder."*

François Fornieri, CEO of Mithra Women's Health: *"I would like to thank all the outgoing directors for what they have accomplished. Through their care and diligence, they have undoubtedly been the architects of the success that the company is experiencing today. More importantly, Marc Coucke has proven to be a major support in all the steps we have had to take. His vision and unfailing energy have been the most valuable resources the company has ever been able to draw on. With all of the new members of the Board of Directors and their expertise, we will work to continue the path we have taken to successfully lead Mithra to its next phase of development. »*

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 - press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes

concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

A circular icon with a teal background and white text that reads "News Alerts".

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)